Non-invasive diagnosis and follow-up of benign liver tumours - Archive ouverte HAL Access content directly
Journal Articles Clinics and Research in Hepatology and Gastroenterology Year : 2022

Non-invasive diagnosis and follow-up of benign liver tumours

(1, 2) , (3, 4) , (5) , (6) , (7) , (8) , (9) , (5) , (10) , (3, 4) , (11, 12) , (13) , (1, 2)
1
2
3
4
5
6
7
8
9
10
11
12
13

Abstract

Hepatocellular benign liver tumours are mainly developed on normal liver and include hepatic hemangioma, focal nodular hyperplasia and hepatocellular adenoma from the most frequent to the less frequent. The diagnosis of hepatic hemangioma and of simple hepatic biliary cysts can be performed using non-invasive criteria using liver ultrasonography or contrast enhanced MRI. Most of the time the diagnosis of focal nodular hyperplasia can be achieved using contrast-enhanced ultrasonography or contrast enhanced MRI with an additional value of hepatobiliary contrast-agent in this setting. Rarely, if a doubt persists, a tumour and non-tumour liver biopsy can be required in order to establish the diagnosis. As hepatic hemangioma, simple hepatic biliary cysts and focal nodular hyperplasia are not associated with complications, they don't require any treatments or follow-up. Hepatocellular adenomas are mainly diagnosed at histology on surgical samples or liver biopsy even if some radiological features are highly suggestive of several subtypes of hepatocellular adenomas. Finally, the management of hepatocellular adenomas should be guided according to the tumour size, gender but also to the molecular subtypes.
Embargoed file
Embargoed file
Ne sera jamais visible

Dates and versions

inserm-03651293 , version 1 (25-04-2022)

Identifiers

Cite

Jean Charles Nault, Jean Frederic Blanc, Lucile Moga, Julien Calderaro, Thông Dao, et al.. Non-invasive diagnosis and follow-up of benign liver tumours. Clinics and Research in Hepatology and Gastroenterology, 2022, 46 (1), pp.101765. ⟨10.1016/j.clinre.2021.101765⟩. ⟨inserm-03651293⟩
19 View
7 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More